Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ARB Marketers May Be Tense After AHRQ Comparative Effectiveness Report

Executive Summary

A comparative effectiveness review from the Agency for Healthcare Research and Quality comparing ACE inhibitors and ARBs may create challenges for brand manufacturers in formulary negotiations

You may also be interested in...



Baucus Flags Comparative Effectiveness As Priority For Senate Medicare Bill

Comparative effectiveness research continues to have traction in Congress. The issue has been flagged as a priority item for inclusion in the Senate Finance Committee forthcoming package of Medicare and other health care provisions, according to a top health aide to committee Chairman Max Baucus, D-Mont

Savings From Expanded Comparative Effectiveness Could Be Decade Away – CBO

Although medical product comparative effectiveness research is often seen as a way to better target health care spending, an expanded research effort may not yield direct savings for at least 10 years, Congressional Budget Office Director Peter Orszag said

Hypertensive Label Changes Could Remedy Under-Treatment Problem -Cmte

More explicit dosing instructions in labeling might be the best way to urge physicians to more aggressively manage the under-treated hypertensive population, FDA's Cardio-Renal Advisory Committee said at an April 18 meeting to review a first-line claim for Bristol-Myers Squibb's Avalide

Related Content

UsernamePublicRestriction

Register

PS048987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel